Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years

Tatiana Chirkova1, Christian Rosas-Salazar2, Tebeb Gebretsadik3, Samadhan J. Jadhao1, James D. Chappell2, R. Stokes Peebles Jr.4, William D. Dupont3, Dawn C. Newcomb4, Sergejs Berdnikovs5, Peter J. Gergen6, Tina V. Hartert2,4* and Larry J. Anderson1*

1 Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, United States, 2 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States, 3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States, 4 Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States, 5 Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States, 6 Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, United States

Background: It is unknown whether RSV infection in infancy alters subsequent RSV immune responses.

Methods: In a nested cohort of healthy, term children, peripheral blood mononuclear cells (PBMCs) were collected at ages 2-3 years to examine RSV memory T cell responses among children previously RSV infected during infancy (first year of life) compared to those RSV-uninfected during infancy. The presence vs. absence of infant RSV infection was determined through a combination of RSV molecular and serologic testing. Memory responses were measured in RSV stimulated PBMCs.

Results: Compared to children not infected with RSV during the first year of life, children infected with RSV during infancy had lower memory T cell responses at ages 2-3 years to in vitro stimulation with RSV for most tested type-1 and type-17 markers for a number of memory T cell subsets.

Conclusions: RSV infection in infancy has long-term effects on memory T cell responses. This is the first study to show the potential for RSV infection in infancy to have long-term effects on the immune memory irrespective of the severity of the infection. Our results suggest a possible mechanism through which infant RSV infection may result in greater risk of subsequent childhood respiratory viral morbidity, findings also relevant to vaccine development.

Keywords: asthma, children, epidemiology, memory immune response, infants, peripheral blood mononuclear cells, RSV (respiratory syncytial virus)

Abbreviations: CI, Confidence interval; INSPIRE, Infant Susceptibility to Pulmonary Infections and Asthma Following Respiratory; Syncytial Virus Exposure Study; PBMCs, Peripheral blood mononuclear cells; RSV, Respiratory syncytial virus; TCM, T central memory cells; TEM, T effector memory cells; TEMRA, T effector memory cells expressing CD45RA; IFN-γ, Interferon gamma; TNF-α, Tumor necrosis factor alpha; IL-2, Interleukin 2; T-bet, T-box expressed in T cells; GATA3, G-A-T-A-3 binding protein; RORγt, Retinoic acid-related orphan receptor gamma t.
INTRODUCTION

Respiratory syncytial virus (RSV) is a ubiquitous, seasonal pathogen that infects the ciliated epithelium of the upper and lower respiratory tracts and is the single most important cause of infant lower respiratory tract infections worldwide (1–5). Most children are infected by RSV by age 2 years, but RSV then causes repeat infections throughout life; the serious complications of infection are most common in infancy and in the elderly (4, 6, 7). Infant infection is likely to have the greatest impact on immune development, given that the infant’s immune system is rapidly developing. Thus, understanding the long-term effects of RSV infection during the critical period of the developing infant immune system is important in understanding and preventing RSV’s contribution to chronic respiratory morbidity (8–16). Many clinical studies of RSV’s role in long-term respiratory morbidity have focused on severe RSV infection, i.e. children hospitalized with RSV-associated bronchiolitis, compared to children without severe RSV disease but who may have been infected with RSV. This design may fail to capture initial life exposure to RSV and the full clinical spectrum of disease, thereby limiting systematic analyses of long-term effects of RSV infection on immune memory. For the current study, we used a nested cohort of a larger population-based cohort (17) where children were prospectively followed from early infancy throughout the first year of life, with RSV infection status determined by PCR of respiratory secretions during RSV season and RSV antibody studies at 1 year of age. The nested cohort allowed us to compare RSV memory T cells from 2-3 year old children who were infected with RSV during their first year of life to RSV memory T cells from children who remained uninfected at 1 year of age, enabling determination of whether RSV infection during infancy induces a different memory T cell response than infection later in life.

MATERIALS AND METHODS

Overview of the Study Population and Design

The Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure study (INSPIRE) is a population-based, birth cohort of healthy, term children specifically designed to determine the presence vs. absence of RSV infection in infancy (i.e., the first year of life) on subsequent childhood respiratory morbidity. Eligible children were overall healthy, born at term and non-low birthweight, and enrolled near birth, between June and December of 2012 and 2013 (i.e. would be ≤6 months of age at the beginning of their first RSV season, November to March in our region) (10, 18). An a priori designed nested cohort of children with and without infant RSV infection included longitudinal measures of memory T cell responses at ages 2-3 years (completed) and age 6-7 years (ongoing) to understand the long-term impact of infant RSV infection on immune outcomes. The detailed methods for INSPIRE have been previously reported, and an overview of this study design is depicted in Figure 1 (17). The Institutional Review Board of Vanderbilt University approved this study (IRB# 111299) and one parent of each child provided informed consent for their participation.

Determination of RSV Infection in Infancy

For the ascertainment of RSV infection in infancy, we first conducted passive and active surveillance during each child’s first RSV season. In children who met pre-specified criteria for an acute respiratory illness, a nasal wash was tested for RSV using reverse transcription-quantitative PCR (17, 19). In addition, RSV serum antibody titers were measured in blood samples obtained at age 1-year by enzyme-linked immunosorbent assay (ELISA) as previously described (20). Briefly, the ELISA detects IgG antibodies to RSV in infected tissue culture lysates containing group A and B antigens; uninfected tissue culture lysate serves as a control for nonspecific antibody binding. Children were then grouped into those infected vs. not infected with RSV in infancy using a hierarchical categorization with mutually exclusive group membership.

Nested Cohort for Peripheral Blood Mononuclear Cells (PBMCs) Studies

To understand the impact of RSV infection in infancy on RSV memory T cell responses, we collected blood from a nested cohort of 75 children enrolled in the INSPIRE cohort who were or were not infected with RSV during infancy. The PBMCs were collected at ages 2-3 years (median age [interquartile age] = 2.83 [2.25-3.83] years).
PBMC Isolation
For PBMC isolation, up to ~30 ml of blood was collected using the BD Vacutainer® CPT™ system (Becton Dickinson, New Jersey, United States) and PBMCs were separated according to the manufacturer’s instructions. PBMCs were subsequently counted, divided into aliquots, and stored in liquid nitrogen until further analyses.

RSV Propagation and Purification
RSV A2001/3-12 (RSV 3-12) was propagated in HEp-2 cells and purified by ultracentrifugation through a 20% sucrose cushion as previously described (21, 22). Briefly, HEp-2 cells were maintained in MEM media (Gibco, Thermo Fisher Scientific, Massachusetts, USA) with 5% FBS (HyClone, Thermo Fisher Scientific, Massachusetts, USA), and cells were infected with a low passage stock RSV 3-12 virus at multiplicity of infection (MOI) = 0.01 TCID₅₀/ml. The high titer virus was collected by ultracentrifugation, and supernatant was clarified by centrifugation at 1000 x g at 4°C for 10 min. The clarified supernatant was overlayed on a 20% of sterile sucrose solution, and virus was pelleted by ultracentrifugation. The virus was resuspended in serum-free MEM medium and stored at -80°C. The infectivity titer of RSV was assessed in a TCID₅₀ assay in Hep-2 cells; the stimulation dose for PBMC experiments was an MOI of 1 TCID₅₀.

Flow Cytometry Analysis
Cells were fixed, permeabilized, and stained for flow cytometry with Zombie Violet (Biolegend), eFluor-450 anti-CD4 (Biolegend), eFluor-560 anti-CD8 (Biolegend), PE anti-CD45RA (Biolegend, California, United States), FITC anti-CD3 (Biolegend), R-phycoerythrin (eBioscience) labeled antibodies against T-bet (Biolegend), GATA3, and RORγt markers. Positive control SEB was used to gate positive marker expressing cells (Figures S1, S2). The mean of mock-stimulated wells was subtracted from the corresponding mean of RSV-stimulated replicates prior to statistical analyses.

Statistical Analyses
We used unadjusted and adjusted generalized least squares regression models to determine the relationship of infants’ RSV infection status with the memory T cell responses while accounting for clustered data. The adjusted models controlled for the child’s sex and race or ethnicity. Statistical significance was defined as p<0.05. We report both negative and as well as positive results for the pre-specified the immune marker comparisons between RSV infected vs RSV uninfected status, and no adjustments were made for multiple tests.

RESULTS
Our memory T cell studies were performed using PBMC collected from 75 children at ages 2-3 years enrolled in the nested cohort within the larger INSPIRE birth cohort. The demographics for this nested cohort are shown in Table 1. Children included in the INSPIRE cohort were followed after birth with their RSV status tested by PCR and serology throughout the first year of life. The detailed description of INSPIRE and RSV testing has been previously reported (17).

Fifty-six (75%) of the 75 study children (Table 2) had documented RSV infection during their first year of life, i.e. had RSV infection confirmed by either PCR or serology assay. Control subjects (25% of cohort) did not have documented RSV infection during their first year of life, although they were likely subsequently infected during their second and/or third year and before the PBMCs were collected for this study. Hence our study focused on the effect of infant RSV infection on the T cell responses at 2-3 years of age, irrespective of the occurrence and frequency of the intervening RSV infections.

The main memory T cell subsets, CD4 and CD8 TEM, TCM, and TEMRA, and their functional cytokine responses were studied. PBMC were stimulated in vitro with the purified RSV virus and percentage of cells producing IFN-γ, IL-2, TNF-α, GATA3 and RORγt were determined within each memory T cell subset. Responses of children exposed to RSV in infancy (n=56) were compared to those who did not have documented RSV infection in the first year of life (n=19).
Children infected with RSV in infancy had significantly lower memory T cell responses to in vitro stimulation with RSV 3-12 for most tested type-1 (IFN-γ, IL-2) and type-17 (RORγt) markers (Figure 2). These associations remained significant in both unadjusted and adjusted models for a number of marker-expressing memory subsets, including CD8 TEM and CD8 TEMRA IFN-γ; CD4 TEM IL-2; and CD4 TCM, CD4 TEM, and CD8 TEM RORγt (Table 3). T-bet and TNF-α responses displayed decreasing trends in the effect sizes among children infected with RSV in infancy. Interestingly, the frequencies of GATA3-expressing cells trended slightly towards an increase in the infant RSV-positive group but the effect size was relatively small. Differences in T-bet, TNF-α and GATA3 were not found to be statistically significant (Figure 3).

**DISCUSSION**

This is the first study to show an effect of infant RSV infection on the RSV memory T cell response later in life, irrespective of the severity of the first RSV infection in infancy, and of the occurrence and frequency of any subsequent RSV infections. The population-based INSPIRE birth cohort (almost 2000 children enrolled at birth) that included longitudinal PCR surveillance for RSV during the first year of life, and RSV serology at 1 year to capture any missed infections, allowed us to achieve a fairly large number of participants with documented presence or absence of RSV infection during infancy to conduct T cell response assessment in subsets with and without infant RSV infection. Blood collection at 2-3 years of age enabled us to comprehensively evaluate T cell responses imprinted by the infant (first year of life) RSV exposure and persisting later in life irrespective of subsequent infections, leading to the first evidence from human studies that RSV memory T cell responses differ depending on when during early life infection occurred.

Our data show that infant RSV infection dampens T cell responses regardless of the severity of infection or subsequent re-infections with RSV. To our knowledge, only one other similar study has been conducted (25). In contrast to ours, this study found that PBMCs from children with RSV infection in infancy produce higher levels of IFN-γ and IL-2 following in vitro RSV infection later in life. However, this study was small (n=18), only assessed undifferentiated PBMC responses just beyond infancy at age ~1.2 years, and did not include statistical comparisons (25). The role of RSV infection in infancy on later childhood respiratory morbidity is also supported by numerous in vitro

**TABLE 1** | Demographic characteristics of children in nested cohort.

|                      | Nested cohort (all) (N = 75) | Infant RSV infection (N = 56) | No infant RSV infection (N = 19) |
|----------------------|------------------------------|-------------------------------|-------------------------------|
| Sex                  | Male 57%                     | 57%                           | 58%                           |
|                      | Female 43%                   | 43%                           | 42%                           |
| Gestational age      | 39.0 (38.0, 40.0)            | 39.0 (38.0, 39.48)            | 39.3 (39.0, 40.0)             |
| Birth weight         | 3447.50 (3135.50, 3703.00)   | (3135.75, 3689.00)            | (3163.50, 3717.00)            |
| Race and ethnicity   | White 55%                    | 52%                           | 63%                           |
|                      | Black 27%                    | 34%                           | 5%                            |
|                      | Hispanic 7%                  | 5%                            | 11%                           |
|                      | Other 12%                    | 9%                            | 21%                           |
| Insurance, %         | Medicaid 60%                 | 66%                           | 42%                           |
|                      | Private 39%                  | 34%                           | 53%                           |
|                      | Other/unknown 1%             | 0                             | 5%                            |
|                      | Breast feeding (ever), %     | 79%                           | 79%                           |
|                      | Daycare during infancy, %    | 41%                           | 43%                           |
|                      | Siblings, %                  | 43%                           | 48%                           |

**TABLE 2** | Infant RSV infection status of children in nested cohort.

|                      | Nested cohort (all) (N = 75) | Infant RSV infection (N = 56) | No infant RSV infection (N = 19) |
|----------------------|------------------------------|-------------------------------|-------------------------------|
| RSV infection status | Median RSV IgG antibody titer (IQR) | 3743.5 (154.5, 7309.5) | 5764 (2571, 10736) |
|                      | RSV PCR + 73%                | 98%                           | 0                             |
|                      | RSV serology + 75%           | 100%                          | 0                             |
|                      | Both 73%                     | 98%                           | 0                             |
|                      | Neither 25%                  | 0                             | 100%                          |

*The assay limit detection is 200. Values <200 indicate no RSV antibody was detected.*
and animal studies that provide evidence for potential mechanisms through which early-life RSV infection may contribute to chronic airway diseases by impairing regulatory T cell function (15, 26, 27). A study by Tusker et al. using a murine model of RSV infection demonstrated differences in long-term T cell responses between animals infected with RSV as neonates and those exposed to the primary RSV infection as adults (28). Similar to our clinical findings, neonatal mice infected with RSV exhibited impaired type-1 responses to secondary RSV infection in adulthood. Interestingly, even though neonatally infected mice developed protection against later re-infection with RSV, they had significantly lower expression of IFN-γ and higher levels of IL-4 and IL-5 (type-2 responses) compared to animals primed as adults. Our findings suggest that RSV infection in infancy attenuates later antiviral type-1 and type-17 memory responses. Although frequencies of GATA3-expressing cells rose slightly following RSV stimulation of PBMCs from children infected during infancy, we did not observe significant increases in this measure of Th2 responses among these participants. However, it is possible that RSV infection in infancy could alter expression of other markers of CD4 Th2 and/or affect CD8 Th2 responses.

Age-related differences in innate cytokine responses to RSV infection have been demonstrated, and the importance of this early response is supported by polymorphisms in many early innate genes associated with severe RSV infection (29). Genetic predisposition may result in the dampened Th1 responses to RSV and skewing toward the Th2 and Th17 polarization contributing to other respiratory morbidity, although not all studies demonstrate that infant RSV infection results in a Th2-biased memory. We observed significantly higher frequencies of RORγt-expressing T cells obtained from children who did not have RSV infection in infancy as compared to early-life RSV-infected participants. Some clinical data suggest a definitive role of type-17 responses in the less severe outcomes or improved recovery from RSV infection (30). Infants 6 months and younger with moderate infection were shown to have higher IL-17 plasma levels than infants with severe RSV disease (31), and IL-17 levels were significantly elevated in non-ventilated vs. ventilated RSV-infected pediatric patients at the point of hospital discharge (32). Several animal studies also demonstrate significant differences in antiviral memory T cell responses based on age of primary RSV infection, which together with our results, highlight early life as a critical window impacting memory T cell responses (28, 33).

### TABLE 3
The association of the absence of RSV infection in infancy with memory T cell responses at ages 2-3 years after in vitro stimulation with RSV

| Immune marker | T cell subset | Unadjusted analyses | Adjusted analyses† | p-value | p-value |
|---------------|--------------|---------------------|---------------------|---------|---------|
| IFN-γ         | CD8+ TEM     | 0.88 (0.05 to 1.70) | 0.04                | 0.86 (0.02 to 1.69) | 0.04 |
|               | CD8+ TEMRA   | 1.12 (0.19 to 2.06) | 0.02                | 1.03 (0.11 to 1.98) | 0.03 |
| IL-2          | CD4+ TEM     | 1.06 (0.06 to 2.06) | 0.04                | 1.05 (0.03 to 2.06) | 0.04 |
| RORγt         | CD4+ TEM     | 1.89 (0.47 to 3.31) | 0.009               | 1.83 (0.40 to 3.27) | 0.01 |
|               | CD8+ TEM     | 1.70 (0.27 to 3.12) | 0.02                | 1.66 (0.22 to 3.11) | 0.02 |
|               | CD8+ TEMRA   | 1.75 (0.14 to 3.56) | 0.03                | 1.68 (0.05 to 3.31) | 0.04 |

CI, Confidence interval; RSV, Respiratory syncytial virus; T$_{CM}$, T central memory cells; T$_{EM}$, T effector memory cells; T$_{EMRA}$, T effector memory cells expressing CD45RA.

*The estimates were obtained from unadjusted and adjusted generalized least squares regression models to account for clustered data. The reference group was children with RSV infection in infancy. The β estimate denotes the effect of the absence of RSV infection in infancy on a T cell subset response relative to mock following the in vitro stimulation with RSV for a priori selected type-1 (IFN-γ and IL-2) and type-17 (RORγt) immune markers. Only associations that were significant in bivariate analyses are shown.

†The statistical analyses were conducted in children with complete data.
we detected in children not infected during the responses we measured. It is possible that the higher PBMC possibility that other pathogens or vaccines might have affected responses strictly after RSV stimulation, we cannot exclude the infections may also play a role, even though we assessed cell thus precluding adjusting for multiple covariates. Other viral labor-intensive nature of these studies the sample size was small, have biased our results towards the null. Due to the cost and not infected with RSV in infancy. However, this likely would have had a substantial impact on results. All children would have been RSV exposed, both previously infected and RSV naïve been acutely infected at the time of collection. Finally, there was a mix of response differences including no differences, increases and decreases in response levels between the two groups. Though our sample size is limited, it is, nevertheless, relatively large when considering other studies of childhood T cell immune responses to RSV (34–39). Lastly, our study does not address the basis of age associated patterns of T cell responses to early-life RSV infection, though we recognize that immune responses to viral infection do not occur in isolation and that other host-pathogen interactions such as the airway epithelial cell responses and the microbiome may contribute to differences in our clinical outcomes.

In summary, children who were infected with RSV during their first year of life have dampened antiviral memory T cell responses to RSV at age 2-3 years compared to children who were not infected with RSV during their first year of life, suggesting that early life infection shapes the developing immune system. These results highlight the impact of infant RSV infection may have on anti-viral immunity. It is possible that alterations in the RSV memory response affect responses to other viral infections and explain in part the enhanced susceptibility to respiratory viral infection and virus-triggered asthma exacerbations. Also, the influence of RSV infection on the developing immune system, and memory T cells responses in particular, may be relevant to other immune responses including vaccine associated responses.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The Institutional Review Board of Vanderbilt University approved this study (IRB# 111299) and one parent of each child provided informed consent for their participation. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS
TC, CR-S, TG, WD, RP, TH, and LA contributed to the conception of the study and/or the study design. RP, LA, and TH obtained the research funding supporting this study. TC, SJ, JC, DN, and LA contributed to the sample processing and laboratory assays. TC, CR-S, TG, WD, and TH conducted the statistical analyses. All authors contributed to the interpretation of the data. TC, CR-S, TG, WD, TH, and LA wrote the initial version of the manuscript. All authors reviewed this initial version, revised it critically for important intellectual content, and approved the final version. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors contributed to the article and approved the submitted version.
FUNDING
This work was supported in whole or in part with funds from the National Institute of Allergy and Infectious Diseases (under award numbers U19AI095227 and K24AI177930); the Vanderbilt Institute for Clinical and Translational Research (grant support from the National Center for Advancing Translational Sciences under award number UL1TR000445); the National Heart, Lung, and Blood Institute (under award number K23HL148638); the Parker B. Francis Fellowship Program; and the Department of Pediatrics at Vanderbilt University Medical Center (grant support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number K12HD087023).

ACKNOWLEDGMENTS
We would like to thank Donald H. Arnold, Alyssa Bednarek, Andrew Bender, Steven M. Brunwasser, Sandra Alvarez-Macias, Teresa M. Chipps, Alexandra S. Connolly, Kaitlin M. Costello, Suman R. Das, Marian T. Dorst, Roxanne Filardo-Collins, Rebecca Gammell, Kayla Goodman, Karin Han, Anca M. Ifrim, Ashudee Kirk, Emma K. Larkin, Jessica Levine, Zhouwen Liu, Christian E. Lynch, Megan McCollum, Rendie McHenry, Kelsie McMurtry, Patricia A. Minton, Paul E. Moore, Barron L. Patterson, Fernando P. Polack, Sara Reiss, Theresa Rogers, Patty Russell, Meghan H. Shilts, Britney M. Snyder, Stephanie Steen, ZhengZheng Tang, Kedir N. Turi, Shanda Vereen, Madison Wagener, Kimberly B. Woodward, and Pingsheng Wu from the Center for Asthma Research at Vanderbilt University Medical Center; the Pediatric/Winship Flow Cytometry Core of the Department of Pediatrics at Emory University School of Medicine; Mackenzie E. Coden and Brian M. Jeong from Northwestern University Feinberg School of Medicine; Nathan Dyjack and Jamie L. Everman from National Jewish Health; Joy Laurienzo Panza from the National Institute of Allergy and Infectious Diseases; and all the INSPIRE participants and their families for their involvement in and dedication to this study.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.826666/full#supplementary-material

Supplementary Figure 1 | Flow cytometry gating strategy for PBMC studies. PBMCs collected at age 2-3 years were stimulated with clinical strain RSV A2001/3-12 at MOI = 1 for 72 h. Cells were washed, stained for surface markers, fixed, permeabilized and stained intracellular with fluorescent-labeled antibodies to detect intracellular IFN-γ, TNFα, IL-2, T-bet, and RORγt. Percentages of cells expressing these cytokines and transcription factors were determined within CD4 and CD8 memory T cell subsets: TCM, TEM, and TEMRA. CD4 and CD8 memory T cell subsets were gated based on CCR7 and CD45RA expression within CD8 positive cells after consecutive doublet, nonlymphocyte and dead cell exclusion. Gating for cells expressing cytokines or transcription factors was performed using SEB-stimulated same specimen replicates as a positive gate control and gated naive T cell population of the same-specimen replicates as a negative gate control.

Supplementary Figure 2 | Representative flow cytometry plots of cells expressing cytokine and transcription factors in PBMCs after in vitro stimulation with RSV 3-12: PBMCs collected at age 2-3 years were stimulated with clinical strain RSV A2001/3-12 at MOI = 1 for 72 h. Cells were washed, stained for surface markers, fixed, permeabilized and stained intracellular with fluorescent-labeled antibodies to detect intracellular IFN-γ, TNFα, IL-2, T-bet, and RORγt. Percentages of cells expressing these cytokines and transcription factors were determined within CD4 and CD8 memory T cell subsets by flow cytometry (plots show CD4 and CD8 TEM subsets).

REFERENCES
1. Li Y, Reeves RM, Wang X, Bassat Q, Brooks WA, Cohen C, et al. Global Patterns in Monthly Activity of Influenza Virus, Respiratory Syncytial Virus, Parainfluenza Virus, and Metapneumovirus: A Systematic Analysis. Lancet Glob Health (2019) 7(8):e1031–45. doi: 10.1016/S2214-109X(19)30264-5
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and Regional Mortality From 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet (2012) 380(9859):2095–128. doi: 10.1016/S0140-6736(12)61728-0
3. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study. Lancet (2017) 390 (10098):946–58. doi: 10.1016/S0140-6736(17)30938-8
4. Falsye AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults. N Engl J Med (2005) 353(17):1749–59. doi: 10.1056/NEJMoa459351
5. Rha B, Cums AT, Lively JY, Campbell AP, Englund JA, Boom JA, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics (2020) 146(1):e20193611. doi: 10.1542/peds.2019-3611
6. Nyiro JU, Kombe IK, Sande CJ, Kipkoche J, Kiyuka PK, Onyango CO, et al. Defining the Vaccination Window for Respiratory Syncytial Virus (RSV) Using Age-Seroprevalence Data for Children in Kilifi, Kenya. PloS One (2017) 12(3):e0177803. doi: 10.1371/journal.pone.0177803
7. Zylbersztejn A, Almossawi O, Godka N, Tompsett D, De Stavola B, Standing JF, et al. Access to Palivizumab Among Children at High Risk of Respiratory Syncytial Virus Complications in English Hospitals. Br J Clin Pharmacol (2021) 88(3):1246–57. doi: 10.1111/bcp.15255
8. Brunwasser SM, Snyder BM, Driscoll AJ, Fell DB, Savitz DA, Feikin DR, et al. The Burden and Long-Term Respiratory Morbidity Associated With Respiratory Syncytial Virus Complications in English Hospitals. J Infect Dis Ther (2017) 3(2):173–83. doi: 10.1186/s41024-017-0151-4
9. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunophylaxis of RSV Infection: Advancing From RSV-IGIV to Palivizumab and Motavizumab. Curr Top Microbiol Immunol (2008) 317:103–23. doi: 10.1007/978-3-540-72416-8_4
10. Wu P, Dupont WD, Griffin MR, Carroll KN, Mitchel EF, Gbegradsadk T, et al. Evidence of a Causal Role of Winter Virus Infection During Infancy in Early Childhood Asthma. Am J Respir Crit Care Med (2008) 178(11):1123–9. doi: 10.1164/rccm.200804-579OC
11. Fauroux B, Simoes EAF, Chochia PA, Paes B, Figueras-Aloy J, Manzoni P, et al. The Burden and Long-Term Respiratory Morbidity Associated With Respiratory Syncytial Virus Infection in Early Childhood. Infect Dis Ther (2017) 6(2):173–97. doi: 10.1007/s40121-017-0151-4
12. Verwey C, Nunes MC, Dangor Z, Madhi SA. Pulmonary Function Sequelae Through the Vaccination Window for Respiratory Syncytial Virus (RSV) Infection in Children: A Systematic Review. Pediatr Pulmonol (2020) 55(7):1567–83. doi: 10.1002/ppul.24804
13. Mejias A, Wu B, Tandon N, Chow W, Varma R, Franco E, et al. Risk of Childhood Wheeze and Asthma After Respiratory Syncytial Virus Infection in Full-Term Infants. Pediatr Allergy Immunol (2020) 31(1):47–56. doi: 10.1111/pa.13131

14. Brenes-Chacon H, García-Mauricio C, Moore-Clingenpeel M, Mertz S, Ye F, Cohen DM, et al. Age-Dependent Interactions Among Clinical Characteristics, Viral Load and Disease Severity in Young Children With Respiratory Syncytial Virus Infection. Pediatr Infect Dis J (2021) 40(2):116–22. doi: 10.1097/INF.0000000000002914

15. Heinenon S, Rodriguez-Fernandez R, Diaz A, Oliva Rodriguez-Pastor S, Ramilo O, Mejias A. Infant Immune Response to Respiratory Viral Infections. Immunol Allergy Clin North Am (2019) 39(3):361–76. doi: 10.1016/j.iac.2019.03.005

16. Simoes EAF, Chirikov V, Botteman M, Kwon Y, Kuznik A. Long-Term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants. J Infect Dis (2020) 221(8):1256–70.

17. Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD, et al. Objectives, Design and Enrollment Results From the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE). BMC Pulm Med (2015) 15:45. doi: 10.1186/s12890-015-0040-0

18. Hall CB, Weinberg GA, Iwane MK, Edwards KM, Staat MA, et al. The Burden of Respiratory Syncytial Virus Infection in Young Infants. N Engl J Med (2009) 360(6):588–98. doi: 10.1056/NEJMoa084877

19. Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, et al. Application of TaqMan Low-Density Arrays for Simultaneous Detection of Multiple Respiratory Pathogens. J Clin Microbiol (2019) 47(6):2175–82. doi: 10.1128/JCM.02270-10

20. Jadhao SJ, Anderson LJ. Detection of RSV Antibodies in Human Plasma by ELISA With Respiratory Syncytial Virus During Neonatal Life Primes for Enhanced Antibody and T Cell Responses on Secondary Challenge. J Infect Dis (2020) 221(8):1256–70.

21. Chirkova T, Boyoglu-Barnum S, Gaston KA, Malik FM, Trau SP, Oomens AGP, et al. Dynamics of Human Respiratory Virus-Specific T Cell Responses in Blood and Airways During Episodes of Common Cold. J Immunol (2008) 181(8):5551–9. doi: 10.4049/jimmunol.181.8.5551

22. Cherukuri A, Chirkov V, Li Y, Wilson J, Shorten M, Soh P, et al. Cytokine Response to Respiratory Syncytial Virus Stimulation of Human Airway Epithelial and Immune Cell Responses. Methods Mol Biol (2016) 1442:41–52. doi: 10.1007/978-1-4939-3878-4_7

23. Chirkova T, Boyoglu-Barnum S, Gaston KA, Malik FM, Trau SP, Oomens AGP, et al. Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses. J Virol (2013) 87(24):13466–79. doi: 10.1128/JVI.01741-13

24. Chirkova T, Ha B, Rimawi BH, Oomens AGP, Hartert TV, Anderson LJ. In Vitro Model for the Assessment of Human Immune Responses to Subunit RSV Vaccines. PLoS One (2020) 15(3):e0229660. doi: 10.1371/journal.pone.0229660

25. Anderson LJ, Tsou C, Potter C, Keyserling HL, Smith TF, Ananaba G, et al. Lymphocytes in Respiratory Syncytial Virus Infection. J Exp Med (2008) 198(8):1277–88. doi: 10.1084/jem.20080391.x

26. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, et al. Multiple Respiratory Pathogens. Application of TaqMan Low-Density Arrays for Simultaneous Detection of Multiple Respiratory Pathogens. J Clin Microbiol (2019) 47(6):2175–82. doi: 10.1128/JCM.02270-10

27. Lynch JP, Werder RB, Currer BF, Sikder MAA, Ullah A, Sebina I, et al. Long-Lasting Total Immune Response in Severe Human Lower Respiratory Infection by Respiratory Syncytial Virus. Pediatr Infect Dis J (2009) 28(10):867–73. doi: 10.1097/INF.0b013e3181a3ea71

28. Faber TE, Schuurhof A, Vonk A, Koppelman GH, Hennus MP, Kimpen JL, et al. IL-1RI Gene Variants and Nasopharyngeal IL-1RA Levels Are Associated With Severe RSV Bronchiolitis: A Multicenter Cohort Study. PLoS One (2012) 7(5):e34361. doi: 10.1371/journal.pone.0034364

29. Conners TJ, Baird JS, Yopes MC, Zens KD, Pette K, Ravidranath TM, et al. Developmental Regulation of Efferctor and Resident Memory T Cell Generation During Pediatric Viral Respiratory Tract Infection. J Immunol (2018) 201(2):432–9. doi: 10.4049/jimmunol.1800396

30. Kitcharoensakkul M, Bacharier LB, Yin-Decle H, Boomer JS, Sajol G, Leung MK, et al. Impaired Tumor Necrosis Factor-α Secretion by CD4 T Cells During Respiratory Syncytial Virus Bronchiolitis Associated With Recurrent Wheeze. Immun Inflamm Dis (2020) 8(1):30–9. doi: 10.1002/iid3.281

31. Sieffer DT, Vu L, You D, McBride A, Taylor R, Jones TL, et al. Respiratory Syncytial Virus Disease Severity Is Associated With Distinct CD8+ T-Cell Profiles. Am J Respir Crit Care Med (2020) 201(3):325–34. doi: 10.1164/rccm.201903-0588OC

32. Raiden S, Sananez I, Remes-Lenicov F, Pandol Sano. Th17 Influence Later Progression to Asthma. Mucosal Immunol (2019) 12(5):777–88. doi: 10.1093/mi/myz021

33. Culley FJ, Pollott J, Openshaw PJ. Age at First Viral Infection Determines the Pattern of T Cell-Mediated Disease During Reinfection in Adulthood. J Exp Med (2002) 196(10):1381–6. doi: 10.1084/jem.20020943

34. Weinberg A, Lambert SL, Canniff J, Yu L, Lang N, Esser MT, et al. Antibody and B Cell Responses to an Investigational Adjuvanted RSV Vaccine for Older Adults. Hum Vaccin Immunother (2019) 15(10):2466–74. doi: 10.1080/21645515.2019.1589282

35. Siefker TJ, Flannigan JC, Radeske BJ, Yee SC, Fireman D, Niederman MS, et al. Respiratory Syncytial Virus Infection in US Infants. J Infect Dis (2012) 216:4551.2019.1589282

36. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, et al. Respiratory Syncytial Virus (RSV) Infcts CD4+ T Cells: Frequency of Circulating CD4+ RSV+ T Cells as a Marker of Disease Severity in Young Children. J Infect Dis (2017) 215(7):1049–58. doi: 10.1093/infdis/jix070

37. Heidema J, Rosen J, Lukens MV, Ketel MS, Scheltens E, Kranendonk ME, et al. Dynamics of Human Respiratory Virus-Specific CD8+ T Cell Responses in Blood and Airways During Episodes of Common Cold. J Immunol (2008) 181(8):5551–9. doi: 10.4049/jimmunol.181.8.5551

Author Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Conflict of Interest: LA has served on respiratory syncytial virus (RSV) vaccine advisory boards for Bavarian Nordic, Novavax, Daichi-Sankyo, ClearPath Vaccines Company, ADVI, and Pfizer. Through Emory University, his laboratory currently receives funding from Pfizer for surveillance studies of RSV infection in adults, from Advaccine Biopharmaceuticals Suzhou Co., Ltd. For serologic studies of RSV vaccine recipients, and from Scigen for animal studies on RSV vaccines. He is a co-inventor on several Centers for Disease Control and Prevention patents on the RSV G protein and its CX3C chemokine motif relative to immune therapy and vaccine development. He is also co-inventor on a patent filing for the use of RSV platform virus-like particles with the F and G proteins for vaccines. TH has served on RSV vaccine advisory boards for Sanofi-Pasteur and Pfizer.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent the official views of the publishers, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chirikova, Rosas-Salazar, Gebretsadik, Jadhao, Chappell, Peebles, Dupont, Newcomb, Berdnikovs, Gergen, Hartert and Anderson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.